Skip to main content
SpringerLink
Log in
Book cover

Skin Cancer Management pp 279–290Cite as

Chemoprevention of Skin Cancer

  • Chapter
  • First Online:

Abstract

This chapter focuses on the use of systemic and topical retinoids in the chemoprevention of skin cancer and will aim to demystify their use in the clinical arena. The use of nonsteroidal anti-inflammatory agents, antioxidants, and tea polyploids will also be addressed. Topical imiquimod, 5-fluoruracil, and photodynamic therapy have been detailed elsewhere (see Chapters 2 and 4).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 1994:372:107–110.

    Google Scholar 

  2. Rudkin GH, Carlsen BT, Chung CY, et al. Retinoids inhibit squamous cell carcinoma growth and intercellular communication. J Surg Res. 2002;103:183.

    Article  CAS  PubMed  Google Scholar 

  3. Verma AK. Retinoids in chemoprevention of cancer. J Biol Regul Homeost Agents. 2003;17:92.

    CAS  PubMed  Google Scholar 

  4. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988;318:1633–1637.

    Article  CAS  PubMed  Google Scholar 

  5. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348;1681–1691.

    Article  PubMed  Google Scholar 

  6. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo controlled study. J Clin Oncol. 1995;13:1933–1938.

    CAS  PubMed  Google Scholar 

  7. Euvrard S, Verschoore M, Touraine J, et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet. 1992;340(8810):48–49.

    Google Scholar 

  8. Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. QJ Med. 1988:68:717–725.

    CAS  Google Scholar 

  9. Kelly JW, Sabto J, Gurr FW, et al. Retinoids to prevent skin cancer in organ transplant recipients. Lancet. 1991:338:1407.

    Article  CAS  PubMed  Google Scholar 

  10. Gibson GE, O’Grady A, Kay EW, et al. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol. 1998:10:42–47.

    Article  CAS  PubMed  Google Scholar 

  11. DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol. 1998:39:S82–S85.

    Article  CAS  PubMed  Google Scholar 

  12. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol. 1999:140:656–660.

    Article  CAS  PubMed  Google Scholar 

  13. George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol. 2002;43:269–273.

    Article  PubMed  Google Scholar 

  14. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant. 2005;19:726–734.

    Article  PubMed  Google Scholar 

  15. Mehrany K, Weenig RH, Lee KK, et al. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol. 2005;53:1067–1071.

    Article  PubMed  Google Scholar 

  16. Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30:642.

    Article  PubMed  Google Scholar 

  17. Martinez JC, Otley CC, Stasko T, et al. Transplant Skin Cancer Collaborative. Defining the course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol. 2003;139:301.

    Article  PubMed  Google Scholar 

  18. Otley CC, Stasko T, Tope WD, et al. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006;32:562–568.

    Article  CAS  PubMed  Google Scholar 

  19. Neuhaus IM, Tope WD. Practical retinoid chemoprophylaxis in solid organ transplant recipients. Dermatol Ther. 2005;18(1):28–33.

    Article  PubMed  Google Scholar 

  20. McKerrow KJ, MacKie RM, Lesko MJ, Pearson C. The effect of oral retinoid therapy on the normal human immune system. Br J Dermatol. 1988:119:313–320.

    Article  CAS  PubMed  Google Scholar 

  21. Tan SR, Tope WD. Effect of acitretin on wound healing in organ transplant recipients. Dermatol Surg. 2004;30:667–673.

    Article  PubMed  Google Scholar 

  22. Sekula-Gibbs S, Uptmore D, Otillar L. Retinoids. J Am Acad Dermatol. 2004;50:405–415.

    Article  PubMed  Google Scholar 

  23. Yaar M, Gilchrest BA. Photoaging: mechanism, prevention and therapy. Br J Dermatol. 2007;157:874–887.

    Article  CAS  PubMed  Google Scholar 

  24. Odom R. Managing actinic keratoses with retinoids. J Am Acad Dermatol. 1998;39:S74–S78.

    Article  CAS  PubMed  Google Scholar 

  25. Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study. Br J Dermatol. 1987;116:549–552.

    Article  CAS  PubMed  Google Scholar 

  26. Euvard S, Kanitkas J, Claudy A. Topical retinoids for the management of dysplastic epithelial lesions. In: Skin Diseases after Organ Transplantation. Montrouge: John Libby Eurotext; 1998:P175–P182.

    Google Scholar 

  27. Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation. 1995;59:714–719.

    Article  CAS  PubMed  Google Scholar 

  28. Smit JV, Cox S, Blokx WAM, van de Kerkhof PCM, deJongh GJ, deJong EMGJ. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol. 2002;147:816–818.

    Article  CAS  PubMed  Google Scholar 

  29. Brenner S, Wolf R, Dascalu DI. Topical tretinoin treatment in basal cell carcinoma. J Dermatol Surg Oncol. 1993;19:264–266.

    CAS  PubMed  Google Scholar 

  30. Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigenes: a randomized trial. J Am Acad Dermatol. 2003;49:83–90.

    Article  PubMed  Google Scholar 

  31. Phillips TJ, Gottlieb AB, Leyden JJ, et al. Efficacy of 0.1% tazarotene cream for treatment of photodamage. Arch Dermatol. 2002;138:1486–1493.

    Article  CAS  PubMed  Google Scholar 

  32. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med. 1999;341:1767–1768.

    Article  CAS  PubMed  Google Scholar 

  33. Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151:148–156.

    Article  CAS  PubMed  Google Scholar 

  34. Peris K, Ferrari A, Fargnoli MC, Piccolo D, Chimenti S. Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma. Dermatol Surg. 2005;31:217–220.

    Article  CAS  PubMed  Google Scholar 

  35. Duvic M, Ni X, Talpur R, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol. 2003;121:902–909.

    Article  CAS  PubMed  Google Scholar 

  36. Bardazzi F, Bianchi F, Parente G. A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ. J Am Acad Dermatol. 2005;52:1102–1104.

    Article  PubMed  Google Scholar 

  37. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 1998;19:723–729.

    Article  CAS  PubMed  Google Scholar 

  38. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25:231–240.

    Article  CAS  PubMed  Google Scholar 

  39. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog. 2003;38:49–58.

    Article  CAS  PubMed  Google Scholar 

  40. Tripp CS, Blomme EA, Chinn KS, Hardy MM, LaCelle P, Pentland AP. Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition in photoprotection. J Invest Dermatol. 2003;121(4):853–861.

    Article  CAS  PubMed  Google Scholar 

  41. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol. 2005;53:966–972.

    Article  PubMed  Google Scholar 

  42. Farooq M, Haq I, Qureshi AS. Cardiovascular risks of COX inhibition: current perspectives. Expert Opin Pharmacother. 2008;9:1311–1319.

    Article  CAS  PubMed  Google Scholar 

  43. Rivers JK, Mclean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol. 1997;133:1239–1242.

    Article  CAS  PubMed  Google Scholar 

  44. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open label assessment of the treatment of actinic keratoses with 3.0% diclofenac sodium topical gel. J Drugs Dermatol. 2004;3(4):401–407.

    PubMed  Google Scholar 

  45. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Aust J Dermatol. 2005;44:40–43.

    Article  Google Scholar 

  46. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 2.5% diclofenac in 2.5% hyaluronic acid gel. Br J Dermatol. 2002;146:94–100.

    Article  CAS  PubMed  Google Scholar 

  47. Katiyar SK, Perez A, Mukhtar H. Green tea polyphenol treatment to human skin prevents formation of ultraviolet light B-induced pyrimidine dimers in DNA. Clin Cancer Res. 2000 Oct;6(10):3864–3869.

    CAS  PubMed  Google Scholar 

  48. Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and skin photoprotection. Int J Oncol. 2001 Jun;18(6):1307–1313.

    CAS  PubMed  Google Scholar 

  49. Katiyar SK, Bergamo BM, Vyalil PK, Elmets CA. Green tea polyphenols: DNA photodamage and photoimmunology. J Photochem Photobiol B. 2001 Dec 31;65(2–3):109–114.

    Article  CAS  Google Scholar 

  50. Yarosh D, Alas LG, Yee V, et al. Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice. Cancer Res. 1992;52:4227–4231.

    CAS  PubMed  Google Scholar 

  51. Yarosh D, Klein J, O’Connor A, et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomized study. Xeroderma Pigmentosum Study Group. Lancet. 2001;357:926–929.

    Article  CAS  PubMed  Google Scholar 

  52. Wright TI, Spencer JM, Flowers FP. Chemoprevention of non-melanoma skin cancer. J Am Acad Dermatol. 2006;54:933–946.

    Article  PubMed  Google Scholar 

  53. Arbeit JM, Riley RR, Huey B, et al. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. Cancer Res. 1999;59:3610–3620.

    CAS  PubMed  Google Scholar 

  54. Ahmad N, Gali H, Javed S, et al. Skin cancer chemopreventive effects of a flavinoid silymarin are mediated via impairment of receptor tryosine kinase signaling and perturbation in cell cycle progression. Biochem Biophys Res Commun. 1998;247:294–301.

    Article  CAS  PubMed  Google Scholar 

  55. Shyong EQ, Lu Y. Effects of genistein on PUVA induced photodamage. Carcinogenesis. 2002;23:317–321.

    Article  CAS  PubMed  Google Scholar 

  56. Cheng AL, Hsu CH, Lin HK, et al. Phase 1 clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–2900.

    CAS  PubMed  Google Scholar 

  57. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin. 2000;50:7–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Director of Transplant Dermatology, Emory University, Atlanta, GA, USA

    Fiona Zwald MD, MRCPI (Assistant Professor)

  2. Division of Dermatology, The Ohio State University, Columbus, OH, USA

    David Lambert MD (Clinical Associate Professor)

Authors
  1. Fiona Zwald MD, MRCPI
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Lambert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. One Hermann Museum Circle , Houston, 77004, U.S.A.

    Deborah F. MacFarlane

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Zwald, F., Lambert, D. (2009). Chemoprevention of Skin Cancer. In: MacFarlane, D.F. (eds) Skin Cancer Management. Springer, New York, NY. https://doi.org/10.1007/978-0-387-88495-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-88495-0_21

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-88494-3

  • Online ISBN: 978-0-387-88495-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation